この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 1999/1/271 分で読めます
Agency Information Collection Activities; Announcement of OMB Approval; Guidance for Industry: Current Good Manufacturing Practice for Blood and Blood Components: (1) Quarantine and Disposition of Units From Prior Collections From Donors with Repeatedly Reactive Screening Test for Antibody to Hepatitis C Virus (Anti-HCV); (2) Supplemental Testing, and the Notification of Consignees and Blood Recipients of Donor Test Results for Anti-HCV
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is announcing that a collection of information entitled ``Guidance for Industry: Current Good Manufacturing Practice for Blood and Blood Components: (1) Quarantine and Disposition of Units From Prior Collections From Donors with Repeatedly Reactive Screening Test for Antibody to Hepatitis C Virus (Anti-HCV); (2) Supplemental Testing, and the Notification of Consignees and Blood Recipients of Donor Test Results for Anti-HCV'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →